Zobraziť v EDS

Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.

Uložené v:
Podrobná bibliografia
Názov: Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
Autori: Giannone, G., Scotto, G., Katsaros, D., De Giorgi, U., Farolfi, A., Borella, F., Cosma, S., Ferrero, A., Mangiacotti, S., Villa, M., Tuninetti, V., Ghisoni, E., Turinetto, M., Mittica, G., Gemmiti, S., Zavallone, L., Aglietta, M., Pasini, B., Di Maio, M., Valabrega, G.
Rok vydania: 2025
Zbierka: Université de Lausanne (UNIL): Serval - Serveur académique lausannois
Predmety: BRCA1 Protein/genetics, BRCA2 Protein/genetics, Drug Hypersensitivity/genetics, Female, Genes, BRCA1, BRCA2, Germ-Line Mutation, Humans, Multicenter Studies as Topic, Observational Studies as Topic, Organoplatinum Compounds/adverse effects, Organoplatinum Compounds/therapeutic use, Retrospective Studies, BRCA, Hypersensitivity reactions, Ovarian cancer, Platinum salts
Popis: Hypersensitivity reactions (HSRs) to platinum are an important issue in the treatment of patients (pts) with ovarian cancer (OC). Germline BRCA mutations have been proposed as a risk factor. We aimed at evaluating the incidence and severity of HSRs to platinum in OC pts. with known BRCA status. We retrospectively analyzed 432 pts. from 5 Italian Centers. In addition, we performed a systematic review and meta-analysis of published series. Four hundred nine pts. received at least one prior platinum-based treatment line: 314 were BRCA wild type (77%) and 95 were BRCA mutated (23%). There was no statistical difference in exposure to platinum. Incidence of any grade HSRs was higher among BRCA mutated pts. [9% vs 18%, p = 0.019] and the time-to-HSRs curves show that the risk increases with the duration of platinum exposure, in BRCA mutated pts. more than in BRCA wild type. A multivariable analysis showed that harboring a germline BRCA mutation was related to a higher incidence of HSRs (HR: 1.84, 95% CI 1.00-3.99, p = 0.05) while having received pegylated liposomal doxorubicin (PLD) was related to a lower incidence of HSRs (HR: 0.03 95% CI 0.004-0.22, p = 0.001). The systematic review confirmed the higher incidence of HSRs in BRCA mutated pts., though heterogeneity among series was significant. In OC pts. with BRCA mutations, there is a significantly higher incidence of HSRs to carboplatin, not justified by longer drug exposure. On the other hand, PLD exerted a protective role in our series.
Druh dokumentu: article in journal/newspaper
Jazyk: English
ISSN: 1095-6859
Relation: Gynecologic oncology; https://iris.unil.ch/handle/iris/228823; serval:BIB_BD3BE28C9923; 000664094500013
DOI: 10.1016/j.ygyno.2021.04.018
Dostupnosť: https://iris.unil.ch/handle/iris/228823
https://doi.org/10.1016/j.ygyno.2021.04.018
Prístupové číslo: edsbas.9FEA8DF1
Databáza: BASE
Popis
Abstrakt:Hypersensitivity reactions (HSRs) to platinum are an important issue in the treatment of patients (pts) with ovarian cancer (OC). Germline BRCA mutations have been proposed as a risk factor. We aimed at evaluating the incidence and severity of HSRs to platinum in OC pts. with known BRCA status. We retrospectively analyzed 432 pts. from 5 Italian Centers. In addition, we performed a systematic review and meta-analysis of published series. Four hundred nine pts. received at least one prior platinum-based treatment line: 314 were BRCA wild type (77%) and 95 were BRCA mutated (23%). There was no statistical difference in exposure to platinum. Incidence of any grade HSRs was higher among BRCA mutated pts. [9% vs 18%, p = 0.019] and the time-to-HSRs curves show that the risk increases with the duration of platinum exposure, in BRCA mutated pts. more than in BRCA wild type. A multivariable analysis showed that harboring a germline BRCA mutation was related to a higher incidence of HSRs (HR: 1.84, 95% CI 1.00-3.99, p = 0.05) while having received pegylated liposomal doxorubicin (PLD) was related to a lower incidence of HSRs (HR: 0.03 95% CI 0.004-0.22, p = 0.001). The systematic review confirmed the higher incidence of HSRs in BRCA mutated pts., though heterogeneity among series was significant. In OC pts. with BRCA mutations, there is a significantly higher incidence of HSRs to carboplatin, not justified by longer drug exposure. On the other hand, PLD exerted a protective role in our series.
ISSN:10956859
DOI:10.1016/j.ygyno.2021.04.018